Literature DB >> 19945923

Aberrations of ERBB2 and TOP2A genes in breast cancer.

Kirsten Vang Nielsen1, Sven Müller, Susanne Møller, Andreas Schønau, Eva Balslev, Ann S Knoop, Bent Ejlertsen.   

Abstract

Copy number changes in TOP2A have frequently been linked to ERBB2 (HER2) amplified breast cancers. To study this relationship, copy number changes of ERBB2 and TOP2A were investigated by fluorescence in situ hybridization (FISH) in two cell lines; one characterized by having amplification of both genes and the other by having amplification of ERBB2 and deletion of TOP2A. The characteristics are compared to findings on paired ERBB2 and TOP2A data from 649 patients with invasive breast cancer from a previously published biomarker study. The physical localization of FISH signals in metaphase spreads from cell lines showed that simultaneous amplification is not a simple co-amplification of a whole amplicon containing both genes. Most gene signals are translocated to abnormal marker chromosomes. ERBB2 genes but not TOP2A genes are present in tandem amplicons, leading to a higher ERBB2 ratio. This observation was confirmed by patient FISH data: among 276 (43% of all patients) abnormal tumors, 67% had different ERBB2 and TOP2A status. ERBB2 amplification with normal TOP2A status was found in 36% of the abnormal tumors (15% of all patients). Simultaneous amplification of both genes was found in 28% of the abnormal tumors (12% of all patients) while TOP2A deletion and ERBB2 amplification was observed in 16% of the abnormal cases (8% of all patients). A small number of tumors had TOP2A amplification (4%) or deletion (6%) without simultaneous changes of the ERBB2 gene. ERBB2 deletion was also observed (5%) but only in tumors with simultaneous TOP2A deletion. The average gene/reference ratio was significantly different: 5.0 for TOP2A but 7.2 for ERBB2 in the amplified tumors (P<0.01). Amplification of the two genes may be caused by different mechanisms, leading to higher level of amplification for ERBB2 compared to TOP2A. In the majority of breast cancer patients, simultaneous aberration of ERBB2 and TOP2A is not explained by simple co-amplification. Copyright 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945923      PMCID: PMC5527893          DOI: 10.1016/j.molonc.2009.11.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  41 in total

1.  Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.

Authors:  Dennis J Slamon; Michael F Press
Journal:  J Natl Cancer Inst       Date:  2009-04-28       Impact factor: 13.506

2.  Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Authors:  Minna Tanner; Jorma Isola; Tom Wiklund; Björn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Nilsson; Jonas Bergh
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Manifestation, mechanisms and mysteries of gene amplifications.

Authors:  Samuel Myllykangas; Sakari Knuutila
Journal:  Cancer Lett       Date:  2005-11-08       Impact factor: 8.679

4.  Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer.

Authors:  Bent Ejlertsen; Henning T Mouridsen; Maj-Britt Jensen; Jørn Andersen; Søren Cold; Per Edlund; Marianne Ewertz; Brita B Jensen; Claus Kamby; Bo Nordenskjold; Jonas Bergh
Journal:  Eur J Cancer       Date:  2007-02-16       Impact factor: 9.162

5.  retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.

Authors:  Ann S Knoop; Helle Knudsen; Eva Balslev; Birgitte B Rasmussen; Jens Overgaard; Kirsten V Nielsen; Andreas Schonau; Katrín Gunnarsdóttir; Karen E Olsen; Henning Mouridsen; Bent Ejlertsen
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

6.  Aberrations of ERBB2 and TOP2A genes in breast cancer.

Authors:  Kirsten Vang Nielsen; Sven Müller; Susanne Møller; Andreas Schønau; Eva Balslev; Ann S Knoop; Bent Ejlertsen
Journal:  Mol Oncol       Date:  2009-11-18       Impact factor: 6.603

Review 7.  Relevance of breast cancer cell lines as models for breast tumours: an update.

Authors:  Marc Lacroix; Guy Leclercq
Journal:  Breast Cancer Res Treat       Date:  2004-02       Impact factor: 4.872

8.  The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.

Authors:  Kirsten Vang Nielsen; Bent Ejlertsen; Susanne Møller; Jan Trøst Jørgensen; Ann Knoop; Helle Knudsen; Henning T Mouridsen
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

Review 9.  HER-2 and topoisomerase II as predictors of response to chemotherapy.

Authors:  Kathleen I Pritchard; Hans Messersmith; Leela Elavathil; Maureen Trudeau; Frances O'Malley; Bindi Dhesy-Thind
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

10.  Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

Authors:  Edurne Arriola; Socorro Maria Rodriguez-Pinilla; Maryou B K Lambros; Robin L Jones; Michelle James; Kay Savage; Ian E Smith; Mitch Dowsett; Jorge S Reis-Filho
Journal:  Breast Cancer Res Treat       Date:  2007-01-27       Impact factor: 4.872

View more
  19 in total

1.  Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.

Authors:  Anna J Zaczek; Aleksandra Markiewicz; Barbara Seroczynska; Jaroslaw Skokowski; Janusz Jaskiewicz; Tadeusz Pienkowski; Wojciech P Olszewski; Jolanta Szade; Piotr Rhone; Marzena Welnicka-Jaskiewicz; Jacek Jassem
Journal:  Oncologist       Date:  2012-08-07

2.  Expression and amplification of Topoisomerase-2α in type 1 and type 2 papillary renal cell carcinomas and its correlation with HER2/neu amplification.

Authors:  Fusun Duzcan; Suleyman Ender Duzcan; Sait Sen; Kutsal Yorukoglu; Vildan Caner; Nilay Sen Turk; Gokhan Ozan Cetin; Canan Kelten; Burcin Tuna; Banu Sarsik; Emre Tepeli
Journal:  Pathol Oncol Res       Date:  2011-04-02       Impact factor: 3.201

3.  BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.

Authors:  Katerina Bouchalova; Marek Svoboda; Gvantsa Kharaishvili; Jana Vrbkova; Jan Bouchal; Radek Trojanec; Vladimira Koudelakova; Lenka Radova; Karel Cwiertka; Marian Hajduch; Zdenek Kolar
Journal:  Tumour Biol       Date:  2015-01-24

4.  Aberrations of ERBB2 and TOP2A genes in breast cancer.

Authors:  Kirsten Vang Nielsen; Sven Müller; Susanne Møller; Andreas Schønau; Eva Balslev; Ann S Knoop; Bent Ejlertsen
Journal:  Mol Oncol       Date:  2009-11-18       Impact factor: 6.603

Review 5.  Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy.

Authors:  Miao Ding; Erlong Zhang; Rong He; Xingyong Wang
Journal:  Cancer Sci       Date:  2013-09-23       Impact factor: 6.716

6.  Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.

Authors:  Olivera Mitrović; Vladan Čokić; Dragoslava Đikić; Mirela Budeč; Sanja Vignjević; Tijana Subotički; Maja Gulan; Snežana Radović; Snežana Furtula
Journal:  Target Oncol       Date:  2013-11-24       Impact factor: 4.493

7.  Biomarkers characterization of circulating tumour cells in breast cancer patients.

Authors:  Rosa Nadal; Ana Fernandez; Pedro Sanchez-Rovira; Marta Salido; María Rodríguez; José Luis García-Puche; Marta Macià; Josep Maria Corominas; Miguel Delgado-Rodriguez; Lucas Gonzalez; Joan Albanell; Mónica Fernández; Francesc Solé; José Antonio Lorente; María José Serrano
Journal:  Breast Cancer Res       Date:  2012-05-03       Impact factor: 6.466

8.  Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Authors:  Pierre-Jean Lamy; Frédéric Fina; Caroline Bascoul-Mollevi; Anne-Claire Laberenne; Pierre-Marie Martin; L'Houcine Ouafik; William Jacot
Journal:  Breast Cancer Res       Date:  2011-02-02       Impact factor: 6.466

9.  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Authors:  George Fountzilas; Christos Valavanis; Vassiliki Kotoula; Anastasia G Eleftheraki; Konstantine T Kalogeras; Olympia Tzaida; Anna Batistatou; Ralf Kronenwett; Ralph M Wirtz; Mattheos Bobos; Eleni Timotheadou; Nikolaos Soupos; George Pentheroudakis; Helen Gogas; Dimitrios Vlachodimitropoulos; Genovefa Polychronidou; Gerasimos Aravantinos; Angelos Koutras; Christos Christodoulou; Dimitrios Pectasides; Petroula Arapantoni
Journal:  J Transl Med       Date:  2012-01-12       Impact factor: 5.531

10.  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.

Authors:  George Fountzilas; Christos Christodoulou; Mattheos Bobos; Vassiliki Kotoula; Anastasia G Eleftheraki; Ioannis Xanthakis; Anna Batistatou; George Pentheroudakis; Nikolaos Xiros; Irene Papaspirou; Anna Koumarianou; Pavlos Papakostas; Dimitrios Bafaloukos; Dimosthenis V Skarlos; Konstantine T Kalogeras
Journal:  J Transl Med       Date:  2012-10-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.